High prevalence of cancer around the globe is expected to escalate the growth of the natural killer cells market

 

Natural Killer cells are described as high, globular lymphocytes that are able to generate natural cytotoxic antibodies against cancer cells in a human body. These cells have the ability to kill even the living cells in a human body and apparently, the natural killer cells can also destroy cancer cells in a patient's body. Natural killer cells can also destroy leukemia, cancer, and lymphomas in humans. And since then, this technology has been improved to more precise results and can be applied in various experimental treatments.

Increasing demand for natural killer cells for the treatment of cancer is a key factor driving the growth of the Natural Killer Cells market. According to the World Health Organization, Cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Moreover, it is also used in the treatment of other infections and liver diseases are again anticipated to augment the growth of the Natural Killer Cells market. The rise in the R&D for the development of specific antibodies for improving the activity of NK cells is further projected to accelerate the growth of the market over the forecast timeframe.

North America is projected to gain significant growth over the forecast period and this is attributed to the high adoption of natural killer cells for the treatment of cancer. According to the National Cancer Institute, Prostate, lung, and colorectal cancers account for an estimated 43% of all cancers diagnosed in men in 2020. For women, the three most common cancers are breast, lung, and colorectal, and they will account for an estimated 50% of all new cancer diagnoses in women in 2020.

Key Developments:

1.      In April 2020, FDA accepts IND for NK Cell Therapy CYNK-001 to treat patients with COVID-19

2.      In August 2020, Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing natural killer (NK) immunotherapies for cancer has announced that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy.

3.      In November 2020, Sanofi has signed a deal to buy Kiadis for €308 million ($358 million). The takeover will give Sanofi full control of an off-the-shelf natural killer (NK) cell platform it is already using to try to enhance its multiple myeloma drug Sarclisa.